An Immune Dysregulation in MPN

Current Hematologic Malignancy Reports

Volumn 9, Issue 4, 2014, Pages 331-339

  Barosi, Giovanni ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Autoimmune disorders; C reactive protein; Cytokines; Essential thrombocythemia (ET); Myeloid derived suppressor cells; Myeloproliferative neoplasm (MPN); Oncoinflammation; Polycythemia vera (PV); Primary myelofibrosis (MF); Regulatory T cells

Indexed keywords

CYTOKINE;

GENETICS; HUMAN; IMMUNOLOGY; MYELOPROLIFERATIVE DISORDER; RISK FACTOR;

CYTOKINES; HUMANS; MYELOPROLIFERATIVE DISORDERS; RISK FACTORS;

EID: 84936750823     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-014-0227-0     Document Type: Review

References (101)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.
2. Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014;2014:149185.
3. Rachidi SM, Qin T, Sun S, Zheng WJ, Li Z. Molecular profiling of multiple human cancers defines an inflammatory cancer-associated molecular pattern and uncovers KPNA2 as a uniform poor prognostic cancer marker. PLoS One. 2013;8(3):e57911.
4. Hasselblach H. Idiopathic myelofibrosis: a clinical study of 80 patients. Am J Hematol. 1990;34(4):291–300.
5. Vainchenker W, Constantinescu SN. JAK/STAT signaling in haematological malignancies. Oncogene. 2013;32(21):2601–13.
6. Squires M, Harrison CN, Barosi G, et al. The relationship between cytokine levels and symptoms in patients (pts) with myelofibrosis (MF) from COMFORT-II, a phase 3 study of ruxolitinib (RUX) vs best available therapy (BAT). Blood. 2013; 122(2), Abstract 2070
7. Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122(25):4047–53. This is an updated analysis of the results obtained with ruxolitinib in myelofibrosis patients after a 3-year follow-up. The results indicate that the drug, an anti-cytokine agent, is able to prolong the survival of patients.
8. Anderson LA, Pfeiffer RM, Landgren O, Gadalla S, Berndt SI, Engels EA. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer. 2009;100(5):822–8.
9. Kristinsson SY, Landgren O, Samuelsson J, Björkholm M, Goldin LR. Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica. 2010;95(7):1216–20.
10. Hemminki K, Liu X, Försti A, Ji J, Sundquist J, Sundquist K. Subsequent leukaemia in autoimmune disease patients. Br J Haematol. 2013;161(5):677–87.
11. Guillot X, Moldovan M, Vidon C, Wendling D. Myelofibrosis-related arthritis successfully treated with hydroxyurea. Case Rep Rheumatol. 2014;2014:869743.
12. Thorsteinsdottir S, Bjerrum OW, Hasselbalch HC. Myeloproliferative neoplasms in five multiple sclerosis patients. Leuk Res Rep. 2013;2(2):61–3.
13. Ayvaz OC, Yavasoglu I, Kadikoylu G, Bozkurt G, Bolaman Z. Thrombocytosis in rheumatoid arthritis: JAK2V617F-positive essential thrombocythemia. Rheumatol Int. 2012;32(1):269–71.
14. Fischer M, Helper DJ, Chiorean MV. Myeloproliferative disorders in patients with inflammatory bowel disease on anti-TNF-α therapy: report of two cases and review of the literature. Inflamm Bowel Dis. 2011;17(2):674–5.
15. Ong A, Quach H, Leech M. Reversal of transfusion dependence by tumor necrosis factor inhibitor treatment in a patient with concurrent rheumatoid arthritis and primary myelofibrosis. J Clin Rheumatol. 2011;17(4):211–3.
16. Muslimani A, Ahluwalia MS, Palaparty P, Daw HA. Idiopathic myelofibrosis associated with dermatomyositis. Am J Hematol. 2006;81(7):559–60.
17. Ito A, Umeda M, Koike T, Naruse S, Fujita N. A case of dermatomyositis associated with chronic idiopathic myelofibrosis. Rinsho Shinkeigaku. 2006;46(3):210–3.
18. Jain V, Maheshwari A, Gulati S, Kabra M, Kalra V. Juvenile rheumatoid arthritis with myelofibrosis with myeloid metaplasia. Indian J Pediatr. 2005;72(9):789–91.
19. Camós M, Arellano-Rodrigo E, Abelló D, et al. Idiopathic myelofibrosis associated with classic polyarteritis nodosa. Leuk Lymphoma. 2003;44(3):539–41.
20. Arellano-Rodrigo E, Esteve J, Giné E, Panés J, Cervantes F. Idiopathic myelofibrosis associated with ulcerative colitis. Leuk Lymphoma. 2002;43(7):1481–3.
21. Hernández-Boluda JC, Jiménez M, Rosiñol L, Cervantes F. Idiopathic myelofibrosis associated with primary biliary cirrhosis. Leuk Lymphoma. 2002;43(3):673–4.
22. Tsiara SN, Christou L, Panteli K, Anastasopoulos D, Bourantas KL. A patient with essential thrombocytosis and multiple sclerosis. Eur J Intern Med. 2000;11(6):345–7.
23. Ros Expósito S, Rodríguez Moreno J, Campoy Reolid E, Roig Escofet D. Idiopathic myelofibrosis associated with rheumatoid arthritis. Med Clin (Barc). 1994;102(7):277.
24. Rondeau E, Solal-Celigny P, Dhermy D, et al. Immune disorders in agnogenic myeloid metaplasia: relations to myelofibrosis. Br J Haematol. 1983;53(3):467–75.
25. Lang JM, Oberling F, Giron C, Mayer S. Autoimmunité et deficit de immunité cellulaire au cours des fibroses primitives de la moelle osseuse. Ann Immunol Paris. 1977;128(1–2):291–3.
26. Caligaris Cappio F, Vigliani R, Novarino A, et al. Idiopathic myelofibrosis: a possible role for immune-complexes in the pathogenesis of bone marrow fibrosis. Br J Haematol. 1981;49(1):17–21.
27. Khumbanonda M, Horowitz HI, Eysker ME. Coomb’s positive hemolytic anemia in myelofibrosis with myeloid metaplasia. Am J Med Sci. 1969;258(2):89–93.
28. Barcellini W, Iurlo A, Radice T, et al. Increased prevalence of autoimmune phenomena in myelofibrosis: relationship with clinical and morphological characteristics, and with immunoregulatory cytokine patterns. Leuk Res. 2013;37(11):1509–15. The paper reports the results of autoimmune tests in 100 patients with MF, and document that 45% of the patients had positive anti-erythrocyte antibodies by mitogen-stimulated direct antiglobulin test, a functional assay able to disclose a latent autoimmunity.
29. Bernhardt B, Valletta M. Lupus anticoagulant in myelofibrosis. Am J Med Sci. 1976;272(2):229–31.
30. Hasselbalch H, Berild D, Paaske-Hansen O. Platelet-associated IgG and IgM in myelofibrosis. Scand J Haematol. 1984;32(5):488–92.
31. Gordon BR, Coleman M, Kohen P, Day NK. Immunological abnormalities in myelofibrosis with activation of the complement system. Blood. 1981;58(5):904–10.
32. Lewis CM, Pegrum GD. Immune complexes in myelofibrosis: a possible guide to management. Br J Haematol. 1978;39(2):233–9.
33. Paquette RL, Meshkinpour A, Rosen PJ. Autoimmune myelofibrosis. A steroid-responsive cause of bone marrow fibrosis associated with systemic lupus erythematosus. Med (Baltimore). 1994;73(3):145–52.
34. Pullarkat V, Bass RD, Gong JZ, Feinstein DI, Brynes RK. Primary autoimmune myelofibrosis: definition of a distinct clinicopathologic syndrome. Am J Hematol. 2003;72(1):8–12.
35. Pillai A, Gautam M, Williamson H, Martlew V, Nash J, Thachil J. Multisystem failure due to three coexisting autoimmune diseases. Intern Med. 2009;48(10):837–42.
36. Bass RD, Pullarkat V, Feinstein DI, Kaul A, Winberg CD, Brynes RK. Pathology of autoimmune myelofibrosis. A report of three cases and a review of the literature. Am J Clin Pathol. 2001;116(2):211–6.
37. Jain P, Lin P, Bueso-Ramos C, Verstovsek S, Pemmaraju N. Primary autoimmune myelofibrosis (MF) with high-grade peripheral T-cell lymphoma (PTCL) NOS. Eur J Haematol. 2013;91(4):378–9.
38. Sacré K, Aguilar C, Deligny C, et al. Lytic bone lesions in lupus-associated myelofibrosis. Lupus. 2010;19(3):313–6.
39. Pereira RM, Velloso ER, Menezes Y, Gualandro S, Vassalo J, Yoshinari NH. Bone marrow findings in systemic lupus erythematosus patients with peripheral cytopenias. Clin Rheumatol. 1998;17(3):219–22.
40. Wanitpongpun C, Teawtrakul N, Mahakkanukrauh A, Siritunyaporn S, Sirijerachai C, Chansung K. Bone marrow abnormalities in systemic lupus erythematosus with peripheral cytopenia. Clin Exp Rheumatol. 2012;30(6):825–9.
41. Takahashi T. Autoimmune myelofibrosis accompanied by Sjögren’s syndrome in a 47, XXX/46, XX mosaic woman. Intern Med. 2014;53(7):783–7.
42. Jones AV, Chase A, Silver RT, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet. 2009;41(4):446–9.
43. Olcaydu D, Harutyunyan A, Jäger R, et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet. 2009;41(4):450–4.
44. Jones AV, Campbell PJ, Beer PA, et al. The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. Blood. 2010;115(22):4517–23.
45. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet. 2008;40(8):955–62.
46. Ferguson LR, Han DY, Fraser AG, et al. Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn’s disease in a New Zealand population. Mutat Res. 2010;690(1–2):108–15.
47. Hermouet S, Vilaine M. The JAK2 46/1 haplotype: a marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasm, and impaired defense against infection? Haematologica. 2011;96(11):1575–9.
48. Varricchio L, Godbold J, Scott SA, et al. Increased frequency of the glucocorticoid receptor A3669G (rs6198) polymorphism in patients with Diamond-Blackfan anemia. Blood. 2011;118(2):473–4.
49. Poletto V, Rosti V, Villani L, et al. A3669G polymorphism of glucocorticoid receptor is a susceptibility allele for primary myelofibrosis and contributes to phenotypic diversity and blast transformation. Blood. 2012;120(15):3112–7. The paper documents that the polymorphism A3669G of the glucocorticoid receptor is a susceptibility factor for myelofibrosis. Since the polymorphism is also a predisposing factor for rheumatoid arthritis, it represents a proof of concept of common genetic predisposition to MPNs and inflammatory disorders.
50. Derijk RH, Schaaf MJ, Turner G, et al. A human glucocorticoid receptor gene variant that increases the stability of the glucocorticoid receptor beta-isoform mRNA is associated with rheumatoid arthritis. J Rheumatol. 2001;28(11):2383–8.
51. Varricchio L, Masselli E, Alfani E, et al. The dominant negative β isoform of the glucocorticoid receptor is uniquely expressed in erythroid cells expanded from polycythemia vera patients. Blood. 2011;118(2):425–36.
52. van Oosten MJ, Dolhain RJ, Koper JW, et al. Polymorphisms in the glucocorticoid receptor gene that modulate glucocorticoid sensitivity are associated with rheumatoid arthritis. Arthritis Res Ther. 2010;12(4):R159.
53. Oddsson A, Kristinsson SY, Helgason H, et al. The germline sequence variant rs2736100_C in TERT associates with myeloproliferative neoplasms. Leukemia. 2014;28(6):1371–4.
54. Wang F, Fu P, Pang Y, et al. TERT rs2736100T/G polymorphism upregulates interleukin 6 expression in non-small cell lung cancer especially in adenocarcinoma. Tumour Biol. 2014;35(5):4667–72.
55. Skov V, Larsen TS, Thomassen M, et al. Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: identification of deregulated genes of significance for inflammation and immune surveillance. Leuk Res. 2012;36(11):1387–92.
56. Skov V, Riley CH, Thomassen M, et al. Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis. Leuk Lymphoma. 2013;54(10):2269–73.
57. Skov V, Larsen TS, Thomassen M, et al. Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis. Eur J Haematol. 2011;87(1):54–60.
58. Kremer M, Horn T, Koch I, et al. Quantitation of the JAK2V617F mutation in microdissected bone marrow trephines: equal mutational load in myeloid lineages and rare involvement of lymphoid cells. Am J Surg Pathol. 2008;32(6):928–35.
59. Pardanani A, Lasho TL, Finke C, et al. Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes. Stem Cells. 2007;25(9):2358–62.
60. Pardanani A, Lasho TL, Finke C, Markovic SN, Tefferi A. Demonstration of MPLW515K, but not JAK2V617F, in in vitro expanded CD4+ T lymphocytes. Leukemia. 2007;21(10):2206–7.
61. Larsen TS, Christensen JH, Hasselbalch HC, Pallisgaard N. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br J Haematol. 2007;136(5):745–51.
62. Bogani C, Guglielmelli P, Antonioli E, Pancrazzi A, Bosi A, Vannucchi AM. B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis. Haematologica. 2007;92(2):258–9.
63. Reeder TL, Bailey RJ, Dewald GW, Tefferi A. Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia. Blood. 2003;101(5):1981–3.
64. Delhommeau F, Dupont S, Tonetti C, et al. Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood. 2007;109(1):71–7.
65. Cervantes F, Hernández-Boluda JC, Villamor N, Serra A, Montserrat E. Assessment of peripheral blood lymphocyte subsets in idiopathic myelofibrosis. Eur J Haematol. 2000;65(2):104–8.
66. Ginsberg HN, Le NA, Gilbert HS. Altered high density lipoprotein metabolism in patients with myeloproliferative disorders and hypocholesterolemia. Metabolism. 1986;35(9):878–82.
67. Ginsberg H, Gilbert HS. Hypocholesterolemia in myeloproliferative diseases with myelofibrosis. Prog Clin Biol Res. 1984;154:345–57.
68. Ginsberg H, Gilbert HS, Gibson JC, Le NA, Brown WV. Increased low-density-lipoprotein catabolism in myeloproliferative disorders. Ann Intern Med. 1982;96(3):311–6.
69. Thiele J, Kvasnicka HM, Boeltken B. Resident bone marrow macrophages in idiopathic (primary) myelofibrosis (IMF): a histochemical and morphometric study on sequential trephine biopsies. Leuk Res. 1999;23(11):983–5.
70. Elliott MA, Verstovsek S, Dingli D, et al. Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res. 2007;31(11):1503–9.
71. Boiocchi L, Espinal-Witter R, Geyer JT, et al. Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease. Mod Pathol. 2013;26(2):204–12.
72. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41(1):49–61.
73. Rameshwar P, Narayanan R, Qian J, et al. NF-kappa B as a central mediator in the induction of TGF-beta in monocytes from patients with idiopathic myelofibrosis: an inflammatory response beyond the realm of homeostasis. J Immunol. 2000;165(4):2271–7.
74. Chang VT, Yook C, Rameshwar P. Synergism between fibronectin and transforming growth factor-β1 in the production of substance P in monocytes of patients with myelofibrosis. Leuk Lymphoma. 2013;54(3):631–8.
75. Kundra A, Baptiste S, Chen C, Sindhu H, Wang JJC. Programmed cell death receptor (PD-1), PD-1 ligand (PD-L1) expression and myeloid derived suppressor cells (MDSC) in myeloid neoplasms implicate the mechanism of IMiD treatment of myelofibrosis. Blood. 2013;122(21) Abstract n. 2837
76. Zhao WB, Li Y, Liu X, Zhang LY, Wang X. Involvement of CD4+CD25+ regulatory T cells in the pathogenesis of polycythaemia vera. Chin Med J (Engl). 2008;121(18):1781–6.
77. + T regulatory cells and causes a silencing of T effector cells in patients with myeloproliferative neoplasms whilst promoting a TH17 phenotype. Blood 2013;122(21) Abstract n 4092
78. + T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α. Blood. 2011;118(8):2170–3.
79. Pourcelot E, Trocme C, Mondet J, et al. Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications. Exp Hematol. 2014;42(5):360–8.
80. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29(10):1356–63.
81. Emadi S, Clay D, Desterke C, et al. IL-8 and its CXCR1 and CXCR2 receptors participate in the control of megakaryocytic proliferation, differentiation, and ploidy in myeloid metaplasia with myelofibrosis. Blood. 2005;105(2):464–73.
82. Hermouet S, Godard A, Pineau D, et al. Abnormal production of interleukin (IL)-11 and IL-8 in polycythaemia vera. Cytokine. 2002;20(4):178–83.
83. Desterke C, Bilhou-Nabéra C, Guerton B, et al. FLT3-mediated p38-MAPK activation participates in the control of megakaryopoiesis in primary myelofibrosis. Cancer Res. 2011;71(8):2901–15.
84. Wehrle J, Seeger TS, Schwemmers S, Pfeifer D, Bulashevska A, Pahl HL. Transcription factor nuclear factor erythroid-2 mediates expression of the cytokine interleukin 8, a known predictor of inferior outcome in patients with myeloproliferative neoplasms. Haematologica. 2013;98(7):1073–80.
85. Le Bousse-Kerdiles MC, Chevillard S, Charpentier A, et al. Differential expression of transforming growth factor-β, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. Blood. 1996;88(12):4534–46.
86. Campanelli R, Rosti V, Villani L, et al. Evaluation of the bioactive and total transforming growth factor β1 levels in primary myelofibrosis. Cytokine. 2011;53(1):100–6.
87. Le Bousse-Kerdiles MC, Martyre MC, Samson M. Cellular and molecular mechanisms underlying bone marrow and liver fibrosis: a review. Eur Cytokine Netw. 2008;19(2):69–80.
88. Vannucchi AM, Bianchi L, Paoletti F, et al. A pathologic pathway linking thrombopoietin, GATA-1 and TGF-β1 in the development of myelofibrosis. Blood. 2005;105(9):3493–501.
89. Wang JC, Chang TH, Goldberg A, Novetsky AD, Lichter S, Lipton J. Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia. Exp Hematol. 2006;34(12):1617–23.
90. Badalucco S, Di Buduo CA, Campanelli R, et al. Involvement of TGFβ1 in autocrine regulation of proplatelet formation in healthy subjects and patients with primary myelofibrosis. Haematologica. 2013;98(4):514–7.
91. Barbui T, Carobbio A, Finazzi G, et al. Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis. Leukemia. 2013;27(10):2084–6.
92. Barbui T, Carobbio A, Finazzi G, et al. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica. 2011;96(2):315–8.
93. Tefferi A, Verstovsek S, Barosi G, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009;27(27):4563–9.
94. Centenara E, Guarnone R, Ippoliti G, Barosi G. Cyclosporin-A in severe refractory anemia of myelofibrosis with myeloid metaplasia: a preliminary report. Haematologica. 1998;83(7):622–6.
95. Barosi G, Rosti V, Vannucchi AM. Therapeutic approaches in myelofibrosis. Expert Opin Pharmacother. 2011;12(10):1597–611.
96. Akhmetshina A, Palumbo K, Dees C, et al. Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis. Nat Commun. 2012;3:735.
97. Tabarroki A, Lindner DJ, Visconte V, et al. Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis. Leukemia. 2014;10. The paper provides evidence that JAK1/JAK2 inhibitor ruxolitinib improves pulmonary hypertension associated with MF and reduces the level of inflammatory cytokines. This may be taken as evidence that pulmonary hypertension in MF has an inflammatory pathogenesis.
98. Avanzini MA, Bernardo ME, Novara F, et al. Functional and genetic aberrations of in vitro-cultured marrow-derived mesenchymal stromal cells of patients with classical Philadelphia-negative myeloproliferative neoplasms. Leukemia. 2014.
99. Silver RT, Kiladjian JJ, Hasselbalch HC. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Rev Hematol. 2013;6(1):49–58.
100. Hasselbalch HC, Riley CH. Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential? Leuk Res. 2006;30(10):1217–25.
101. Mascarenhas J, Li T, Sandy L, et al. Anti-transforming growth factor-β therapy in patients with myelofibrosis. Leuk Lymphoma. 2014;55(2):450–2.